Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30 (2018).
Arnold, M. et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut 66, 683–691 (2017).
Malvezzi, M. et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann. Oncol. 29, 1016–1022 (2018).
Doubeni, C. A. et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut 67, 291–298 (2018).
Stoffel, E. M. & Murphy, C. C. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroenterology 158, 341–353 (2020).
Akimoto, N. et al. Rising incidence of early-onset colorectal cancer – a call to action. Nat. Rev. Clin. Oncol. 18, 230–243 (2021).
Vuik, F. E. et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 68, 1820–1826 (2019).
Siegel, R. L. et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut 68, 2179–2185 (2019).
Lui, R. N. et al. Global increasing incidence of young-onset colorectal cancer across 5 continents: a joinpoint regression analysis of 1,922,167 cases. Cancer Epidemiol. Biomark. Prev. 28, 1275–1282 (2019).
Vuik, F. E. R., Nieuwenburg, S. A. V., Nagtegaal, I. D., Kuipers, E. J. & Spaander, M. C. W. Clinicopathological characteristics of early onset colorectal cancer. Aliment. Pharmacol. Ther. 54, 1463–1471 (2021).
Brenner, D. R. et al. Increasing colorectal cancer incidence trends among younger adults in Canada. Prev. Med. 105, 345–349 (2017).
Chung, R. Y. et al. A population-based age-period-cohort study of colorectal cancer incidence comparing Asia against the West. Cancer Epidemiol. 59, 29–36 (2019).
O’Connell, J. B. et al. Rates of colon and rectal cancers are increasing in young adults. Am. Surg. 69, 866–872 (2003).
Siegel, R. L., Jemal, A. & Ward, E. M. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol. Biomark. Prev. 18, 1695–1698 (2009).
Siegel, R. L. et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djw322 (2017).
Potter, J. D. Rising rates of colorectal cancer in younger adults. BMJ 365, l4280 (2019).
REACCT Collaborative Characteristics of early-onset vs late-onset colorectal cancer: a review. JAMA Surg. 156, 865–874 (2021).
Bailey, C. E. et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 150, 17–22 (2015).
Siegel, R. L. et al. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 70, 145–164 (2020).
Araghi, M. et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int. J. Cancer 144, 2992–3000 (2019).
Venugopal, A. & Carethers, J. M. Epidemiology and biology of early onset colorectal cancer. EXCLI J. 21, 162–182 (2022).
Muller, C., Ihionkhan, E., Stoffel, E. M. & Kupfer, S. S. Disparities in early-onset colorectal cancer. Cells https://doi.org/10.3390/cells10051018 (2021).
McClelland, P. H., Liu, T. & Ozuner, G. Early-onset colorectal cancer in patients under 50 years of age: demographics, disease characteristics, and survival. Clin. Colorectal Cancer 21, e135–e144 (2022).
Gausman, V. et al. Risk factors associated with early-onset colorectal cancer. Clin. Gastroenterol. Hepatol. 18, 2752–2759.e2 (2020).
Murphy, C. C., Wallace, K., Sandler, R. S. & Baron, J. A. Racial disparities in incidence of young-onset colorectal cancer and patient survival. Gastroenterology 156, 958–965 (2019).
Holowatyj, A. N., Ruterbusch, J. J., Rozek, L. S., Cote, M. L. & Stoffel, E. M. Racial/ethnic disparities in survival among patients with young-onset colorectal cancer. J. Clin. Oncol. 34, 2148–2156 (2016).
Sung, J. J. Y. et al. Increasing trend in young-onset colorectal cancer in Asia: more cancers in men and more rectal cancers. Am. J. Gastroenterol. 114, 322–329 (2019).
Holmes, A. J. & Anderson, K. Convergence in national alcohol consumption patterns: new global indicators. J. Wine Econ. 12, 117–148 (2017).
Nishida, C., Uauy, R., Kumanyika, S. & Shetty, P. The Joint WHO/FAO Expert Consultation on diet, nutrition and the prevention of chronic diseases: process, product and policy implications. Public Health Nutr. 7, 245–250 (2007).
Romaguera, D. et al. Consumption of ultra-processed foods and drinks and colorectal, breast, and prostate cancer. Clin. Nutr. 40, 1537–1545 (2021).
Carroll, K. L., Fruge, A. D., Heslin, M. J., Lipke, E. A. & Greene, M. W. Diet as a risk factor for early-onset colorectal adenoma and carcinoma: a systematic review. Front. Nutr. 9, 896330 (2022).
Kwon, J. W. et al. Effects of age, time period, and birth cohort on the prevalence of diabetes and obesity in Korean men. Diabetes Care 31, 255–260 (2008).
Li, H., Boakye, D., Chen, X., Hoffmeister, M. & Brenner, H. Association of body mass index with risk of early-onset colorectal cancer: systematic review and meta-analysis. Am. J. Gastroenterol. 116, 2173–2183 (2021).
Gremaud, A. L. et al. Gamifying accelerometer use increases physical activity levels of sedentary office workers. J. Am. Heart Assoc. https://doi.org/10.1161/JAHA.117.007735 (2018).
Church, T. S. et al. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS ONE 6, e19657 (2011).
Parikh, N. I. et al. Increasing trends in incidence of overweight and obesity over 5 decades. Am. J. Med. 120, 242–250 (2007).
Liu, P. H. et al. Association of obesity with risk of early-onset colorectal cancer among women. JAMA Oncol. 5, 37–44 (2019).
Li, H. et al. Associations of body mass index at different ages with early-onset colorectal cancer. Gastroenterology 162, 1088–1097.e3 (2022).
Murphy, C. C. et al. Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer. Gut 71, 1332–1339 (2022).
Ali Khan, U. et al. Personal history of diabetes as important as family history of colorectal cancer for risk of colorectal cancer: a nationwide cohort study. Am. J. Gastroenterol. 115, 1103–1109 (2020).
Jasperson, K. W., Tuohy, T. M., Neklason, D. W. & Burt, R. W. Hereditary and familial colon cancer. Gastroenterology 138, 2044–2058 (2010).
Patel, S. G., Karlitz, J. J., Yen, T., Lieu, C. H. & Boland, C. R. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol. Hepatol. 7, 262–274 (2022).
Stoffel, E. M. et al. Germline genetic features of young individuals with colorectal cancer. Gastroenterology 154, 897–905.e1 (2018).
Pearlman, R. et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 3, 464–471 (2017).
Kim, J. E. et al. High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer. Exp. Mol. Med. 53, 446–456 (2021).
Mauri, G. et al. Early-onset colorectal cancer in young individuals. Mol. Oncol. 13, 109–131 (2019).
Sanz-Garcia, E., Argiles, G., Elez, E. & Tabernero, J. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann. Oncol. 28, 2648–2657 (2017).
Haigis, K. M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40, 600–608 (2008).
Perea, J. et al. Frequency and impact of KRAS mutation in early onset colorectal cancer. Hum. Pathol. 61, 221–222 (2017).
Colon Cancer Laparoscopic or Open Resection Study Group. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 10, 44–52 (2009).
Ugai, T. et al. Molecular characteristics of early-onset colorectal cancer according to detailed anatomical locations: comparison with later-onset cases. Am. J. Gastroenterol. https://doi.org/10.14309/ajg.0000000000002171 (2023).
Perea, J. et al. Age at onset should be a major criterion for subclassification of colorectal cancer. J. Mol. Diagn. 16, 116–126 (2014).
Stigliano, V., Sanchez-Mete, L., Martayan, A. & Anti, M. Early-onset colorectal cancer: a sporadic or inherited disease? World J. Gastroenterol. 20, 12420–12430 (2014).
Islami, F. et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J. Clin. 68, 31–54 (2018).
Bouvard, V. et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol. 16, 1599–1600 (2015).
Domingo, J. L. & Nadal, M. Carcinogenicity of consumption of red meat and processed meat: a review of scientific news since the IARC decision. Food Chem. Toxicol. 105, 256–261 (2017).
Fahrer, J. & Kaina, B. Impact of DNA repair on the dose-response of colorectal cancer formation induced by dietary carcinogens. Food Chem. Toxicol. 106, 583–594 (2017).
Hammerling, U., Bergman Laurila, J., Grafstrom, R. & Ilback, N. G. Consumption of red/processed meat and colorectal carcinoma: possible mechanisms underlying the significant association. Crit. Rev. Food Sci. Nutr. 56, 614–634 (2016).
Johnson, C. H. et al. Molecular mechanisms of alcohol-induced colorectal carcinogenesis. Cancers https://doi.org/10.3390/cancers13174404 (2021).
Grega, T., Vojtechova, G., Gregova, M., Zavoral, M. & Suchanek, S. Pathophysiological characteristics linking type 2 diabetes mellitus and colorectal neoplasia. Physiol. Res. 70, 509–522 (2021).
Deng, T., Lyon, C. J., Bergin, S., Caligiuri, M. A. & Hsueh, W. A. Obesity, inflammation, and cancer. Annu. Rev. Pathol. 11, 421–449 (2016).
Tarasiuk, A., Mosinska, P. & Fichna, J. The mechanisms linking obesity to colon cancer: an overview. Obes. Res. Clin. Pract. 12, 251–259 (2018).
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S. & Dalamaga, M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism 92, 121–135 (2019).
Yang, Y. et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21. Gastroenterology 152, 851–866.e24 (2017).
Chen, Y. et al. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. Oncotarget 8, 31802–31814 (2017).
Peek, R. M. Jr & Blaser, M. J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer 2, 28–37 (2002).
Islami, F. & Kamangar, F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev. Res. 1, 329–338 (2008).
Francois, F. et al. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol. 11, 37 (2011).
Anderson, W. F. et al. The changing face of noncardia gastric cancer incidence among US non-Hispanic whites. J. Natl Cancer Inst. 110, 608–615 (2018).
Cao, Y. et al. Long-term use of antibiotics and risk of colorectal adenoma. Gut 67, 672–678 (2018).
Aneke-Nash, C., Yoon, G., Du, M. & Liang, P. Antibiotic use and colorectal neoplasia: a systematic review and meta-analysis. BMJ Open Gastroenterol. https://doi.org/10.1136/bmjgast-2021-000601 (2021).
Zhang, J. et al. Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study. Gut 68, 1971–1978 (2019).
Kilkkinen, A. et al. Antibiotic use predicts an increased risk of cancer. Int. J. Cancer 123, 2152–2155 (2008).
Boursi, B., Haynes, K., Mamtani, R. & Yang, Y. X. Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiol. Drug Saf. 24, 534–542 (2015).
Louis, P., Hold, G. L. & Flint, H. J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 12, 661–672 (2014).
Ternes, D. et al. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat. Metab. 4, 458–475 (2022).
Wu, H. J. & Wu, E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 3, 4–14 (2012).
Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492–506 (2020).
David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).
Ahmad Kendong, S. M., Raja Ali, R. A., Nawawi, K. N. M., Ahmad, H. F. & Mokhtar, N. M. Gut dysbiosis and intestinal barrier dysfunction: potential explanation for early-onset colorectal cancer. Front. Cell Infect. Microbiol. 11, 744606 (2021).
Abed, J. et al. Colon cancer-associated Fusobacterium nucleatum may originate from the oral cavity and reach colon tumors via the circulatory system. Front. Cell Infect. Microbiol. 10, 400 (2020).
Sears, C. L. The who, where and how of fusobacteria and colon cancer. Elife https://doi.org/10.7554/eLife.28434 (2018).
Chen, T. et al. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection. Hum. Pathol. 79, 93–101 (2018).
Wu, J., Li, Q. & Fu, X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity. Transl Oncol. 12, 846–851 (2019).
Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195–206 (2013).
Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator annexin A1. EMBO Rep. 20, e47638 (2019).
Flanagan, L. et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1381–1390 (2014).
Kaper, J. B., Nataro, J. P. & Mobley, H. L. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2, 123–140 (2004).
Homburg, S., Oswald, E., Hacker, J. & Dobrindt, U. Expression analysis of the colibactin gene cluster coding for a novel polyketide in Escherichia coli. FEMS Microbiol. Lett. 275, 255–262 (2007).
Oliero, M. et al. Prevalence of pks + bacteria and enterotoxigenic Bacteroides fragilis in patients with colorectal cancer. Gut Pathog. 14, 51 (2022).
Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574, 532–537 (2019).
Chubb, D. et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat. Commun. 7, 11883 (2016).
Archambault, A. N. et al. Cumulative burden of colorectal cancer-associated genetic variants is more strongly associated with early-onset vs late-onset cancer. Gastroenterology 158, 1274–1286.e12 (2020).
Huyghe, J. R. et al. Discovery of common and rare genetic risk variants for colorectal cancer. Nat. Genet. 51, 76–87 (2019).
You, Y. N. et al. Germline cancer risk profiles of young-onset colorectal cancer patients: findings from a prospective universal germline testing and tele-genetics program. Dis. Colon Rectum https://doi.org/10.1097/DCR.0000000000002347 (2022).
Boardman, L. A., Vilar, E., You, Y. N. & Samadder, J. AGA clinical practice update on young adult-onset colorectal cancer diagnosis and management: expert review. Clin. Gastroenterol. Hepatol. 18, 2415–2424 (2020).
Provenzale, D. et al. NCCN Guidelines Insights: colorectal cancer screening, version 1.2018. J. Natl Compr. Canc. Netw. 16, 939–949 (2018).
Valle, L., Vilar, E., Tavtigian, S. V. & Stoffel, E. M. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. J. Pathol. 247, 574–588 (2019).
Ma, H. et al. Pathology and genetics of hereditary colorectal cancer. Pathology 50, 49–59 (2018).
Willauer, A. N. et al. Clinical and molecular characterization of early-onset colorectal cancer. Cancer 125, 2002–2010 (2019).
Broderick, P. et al. Evaluation of NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and SMUG1 genes in familial colorectal cancer predisposition. BMC Cancer 6, 243 (2006).
Yurgelun, M. B. et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J. Clin. Oncol. 35, 1086–1095 (2017).
LaDuca, H. et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet. Med. 22, 407–415 (2020).
Mork, M. E. et al. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J. Clin. Oncol. 33, 3544–3549 (2015).
Zhunussova, G. et al. Mutation spectrum of cancer-associated genes in patients with early onset of colorectal cancer. Front. Oncol. 9, 673 (2019).
You, Y. N. et al. Detection of pathogenic germline variants among patients with advanced colorectal cancer undergoing tumor genomic profiling for precision medicine. Dis. Colon Rectum 62, 429–437 (2019).
Mork, M. E. et al. Outcomes of disease-specific next-generation sequencing gene panel testing in adolescents and young adults with colorectal cancer. Cancer Genet. 235–236, 77–83 (2019).
Tutlewska, K., Lubinski, J. & Kurzawski, G. Germline deletions in the EPCAM gene as a cause of Lynch syndrome – literature review. Hered. Cancer Clin. Pract. 11, 9 (2013).
Ligtenberg, M. J. et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat. Genet. 41, 112–117 (2009).
Edelstein, D. L. et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin. Gastroenterol. Hepatol. 9, 340–343 (2011).
Vasen, H. F. Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment. Pharmacol. Ther. 26 (Suppl. 2), 113–126 (2007).
Valle, L. Genetic predisposition to colorectal cancer: where we stand and future perspectives. World J. Gastroenterol. 20, 9828–9849 (2014).
Aelvoet, A. S., Buttitta, F., Ricciardiello, L. & Dekker, E. Management of familial adenomatous polyposis and MUTYH-associated polyposis; new insights. Best. Pract. Res. Clin. Gastroenterol. 58–59, 101793 (2022).
Peterse, E. F. P. et al. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer 124, 2964–2973 (2018).
Giardiello, F. M. et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am. J. Gastroenterol. 109, 1159–1179 (2014).
Knudsen, A. B. et al. Colorectal Cancer Screening: An Updated Decision Analysis for the U.S. Preventive Services Task Force. Report No. 20-05271-EF-2 (Agency for Healthcare Research and Quality, 2021).
Ko, C. W. et al. AGA Clinical Practice Guidelines on the gastrointestinal evaluation of iron deficiency anemia. Gastroenterology 159, 1085–1094 (2020).
Vajravelu, R. K., Mehta, S. J. & Lewis, J. D., Early-age Onset Colorectal Cancer Testing, Epidemiology, Diagnosis, and Symptoms Study Group. Understanding characteristics of who undergoes testing is crucial for the development of diagnostic strategies to identify individuals at risk for early-age onset colorectal cancer. Gastroenterology 160, 993–998 (2021).
Low, E. E. et al. Risk factors for early-onset colorectal cancer. Gastroenterology 159, 492–501.e7 (2020).
Syed, A. R. et al. Old vs new: risk factors predicting early onset colorectal cancer. World J. Gastrointest. Oncol. 11, 1011–1020 (2019).
Frostberg, E. & Rahr, H. B. Clinical characteristics and a rising incidence of early-onset colorectal cancer in a nationwide cohort of 521 patients aged 18-40 years. Cancer Epidemiol. 66, 101704 (2020).
Krigel, A., Zhou, M., Terry, M. B., Kastrinos, F. & Lebwohl, B. Symptoms and demographic factors associated with early-onset colorectal neoplasia among individuals undergoing diagnostic colonoscopy. Eur. J. Gastroenterol. Hepatol. 32, 821–826 (2020).
Dozois, E. J. et al. Young-onset colorectal cancer in patients with no known genetic predisposition: can we increase early recognition and improve outcome? Medicine 87, 259–263 (2008).
Glover, M., Mansoor, E., Panhwar, M., Parasa, S. & Cooper, G. S. Epidemiology of colorectal cancer in average risk adults 20–39 years of age: a population-based national study. Dig. Dis. Sci. 64, 3602–3609 (2019).
Di Leo, M. et al. Risk factors and clinical characteristics of early-onset colorectal cancer vs. late-onset colorectal cancer: a case-case study. Eur. J. Gastroenterol. Hepatol. 33, 1153–1160 (2021).
Kuipers, E. J. et al. Colorectal cancer. Nat. Rev. Dis. Primers 1, 15065 (2015).
Schreuders, E. H. et al. Colorectal cancer screening: a global overview of existing programmes. Gut 64, 1637–1649 (2015).
World Health Organization. Colorectal Cancer Screening. IARC Handbooks of Cancer Prevention Vol. 17 (IARC, 2019).
Rex, D. K. et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. Am. J. Gastroenterol. 112, 1016–1030 (2017).
Patel, S. G. et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. multi-society task force on colorectal cancer. Gastroenterology 162, 285–299 (2022).
Wolf, A. M. D. et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin. 68, 250–281 (2018).
Davidson, K. W. et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 325, 1965–1977 (2021).
Kalyta, A. et al. Canadian colorectal cancer screening guidelines: do they need an update given changing incidence and global practice patterns. Curr. Oncol. 28, 1558–1570 (2021).
Sung, J. J. Y. et al. Third Asia Pacific consensus recommendation on colorectal cancer screening and postpolypectomy surveillance. Gut 71, 2152–2166 (2022).
Ladabaum, U., Mannalithara, A., Meester, R. G. S., Gupta, S. & Schoen, R. E. Cost-effectiveness and national effects of initiating colorectal cancer screening for average-risk persons at age 45 years instead of 50 years. Gastroenterology 157, 137–148 (2019).
Ladabaum, U., Dominitz, J. A., Kahi, C. & Schoen, R. E. Strategies for colorectal cancer screening. Gastroenterology 158, 418–432 (2020).
Knudsen, A. B. et al. Colorectal cancer screening: an updated modeling study for the US Preventive Services Task Force. JAMA 325, 1998–2011 (2021).
Lew, J. B. et al. Benefits, harms, and cost-effectiveness of potential age extensions to the national bowel cancer screening program in Australia. Cancer Epidemiol. Biomark. Prev. 27, 1450–1461 (2018).
Hampel, H. et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J. Clin. Oncol. 26, 5783–5788 (2008).
Snowsill, T. et al. A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer 15, 313 (2015).
Snowsill, T. et al. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technol. Assess. 21, 1–238 (2017).
Syngal, S. et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am. J. Gastroenterol. 110, 223–262 (2015).
Hunter, J. E. et al. Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Fam. Cancer 16, 377–387 (2017).
Clarke, E. V. et al. Implementation of a systematic tumor screening program for Lynch syndrome in an integrated health care setting. Fam. Cancer 18, 317–325 (2019).
Papke, D. J., Lindeman, N. I., Schrag, D. & Iorgulescu, J. B. Underutilization of guideline-recommended mismatch repair/microsatellite instability biomarker testing in advanced colorectal cancer. Cancer Epidemiol. Biomark. Prev. 31, 1746–1751 (2022).
Mei, W. J. et al. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: a narrative review. Front. Immunol. 13, 1019582 (2022).
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet. Med. 11, 35–41 (2009).
Beard, V. K. et al. Genetic testing in families with hereditary colorectal cancer in British Columbia and Yukon: a retrospective cross-sectional analysis. CMAJ Open 8, E637–E642 (2020).
Bednar, E. M., Sun, C. C., McCurdy, S. & Vernon, S. W. Assessing relatives’ readiness for hereditary cancer cascade genetic testing. Genet. Med. 22, 719–726 (2020).
Ponz de Leon, M. et al. Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. Br. J. Cancer 90, 882–887 (2004).
Koehly, L. M. et al. A social network analysis of communication about hereditary nonpolyposis colorectal cancer genetic testing and family functioning. Cancer Epidemiol. Biomark. Prev. 12, 304–313 (2003).
McGivern, B. et al. Family communication about positive BRCA1 and BRCA2 genetic test results. Genet. Med. 6, 503–509 (2004).
Sanz, J. et al. Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain. Fam. Cancer 9, 297–304 (2010).
Stoffel, E. M. et al. Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin. Gastroenterol. Hepatol. 6, 333–338 (2008).
Whitaker, K. D., Obeid, E., Daly, M. B. & Hall, M. J. Cascade genetic testing for hereditary cancer risk: an underutilized tool for cancer prevention. JCO Precis. Oncol. 5, 1387–1396 (2021).
Forrest, K. et al. To tell or not to tell: barriers and facilitators in family communication about genetic risk. Clin. Genet. 64, 317–326 (2003).
Stoffel, E. M. Cascade genetic testing in families with Lynch syndrome. MiGRC https://migrc.org/resource/cascade-genetic-testing-in-families-with-lynch-syndrome/ (2016).
George, R., Kovak, K. & Cox, S. L. Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases. J. Genet. Couns. 24, 388–399 (2015).
Menko, F. H. et al. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice. Fam. Cancer 18, 127–135 (2019).
Hann, K. E. J. et al. Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review. BMC Public Health 17, 503 (2017).
Srinivasan, S. et al. Stakeholder perspectives on overcoming barriers to cascade testing in Lynch syndrome: a qualitative study. Cancer Prev. Res. 13, 1037–1046 (2020).
Whitworth, P. et al. Impact of payer constraints on access to genetic testing. J. Oncol. Pract. 13, e47–e56 (2017).
Radford, C., Prince, A., Lewis, K. & Pal, T. Factors which impact the delivery of genetic risk assessment services focused on inherited cancer genomics: expanding the role and reach of certified genetics professionals. J. Genet. Couns. 23, 522–530 (2014).
Gustafson, S. L., Pfeiffer, G. & Eng, C. A large health system’s approach to utilization of the genetic counselor CPT(R) 96040 code. Genet. Med. 13, 1011–1014 (2011).
Møller, P. et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch Syndrome Database. Gut 67, 1306–1316 (2018).
Plaschke, J. et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J. Clin. Oncol. 22, 4486–4494 (2004).
Dominguez-Valentin, M. et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet. Med. 22, 15–25 (2020).
Hendriks, Y. M. et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127, 17–25 (2004).
Monahan, K. J. et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut 69, 411–444 (2020).
van Leerdam, M. E. et al. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 51, 1082–1093 (2019).
Jarvinen, H. J. et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118, 829–834 (2000).
Renkonen-Sinisalo, L., Aarnio, M., Mecklin, J. P. & Jarvinen, H. J. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect. Prev. 24, 137–142 (2000).
Barrow, P., Khan, M., Lalloo, F., Evans, D. G. & Hill, J. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br. J. Surg. 100, 1719–1731 (2013).
Goverde, A. et al. Routine molecular analysis for Lynch syndrome among adenomas or colorectal cancer within a national screening program. Gastroenterology 155, 1410–1415 (2018).
Vasen, H. F. et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57, 704–713 (2008).
Björk, J. A., Akerbrant, H. I., Iselius, L. E. & Hultcrantz, R. W. Risk factors for rectal cancer morbidity and mortality in patients with familial adenomatous polyposis after colectomy and ileorectal anastomosis. Dis. Colon Rectum 43, 1719–1725 (2000).
Heiskanen, I., Luostarinen, T. & Jarvinen, H. J. Impact of screening examinations on survival in familial adenomatous polyposis. Scand. J. Gastroenterol. 35, 1284–1287 (2000).
Burt, R. W. et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 127, 444–451 (2004).
Leenen, C. H. et al. Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genet. Med. 18, 966–973 (2016).
LoConte, N. K. et al. Lifestyle modifications and policy implications for primary and secondary cancer prevention: diet, exercise, sun safety, and alcohol reduction. Am. Soc. Clin. Oncol. Educ. Book. 38, 88–100 (2018).
US Department of Health and Human Services. Physical activity guidelines for Americans, 2nd edition. US Department of Health and Human Services https://health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf (2018).
Farinetti, A., Zurlo, V., Manenti, A., Coppi, F. & Mattioli, A. V. Mediterranean diet and colorectal cancer: a systematic review. Nutrition 43-44, 83–88 (2017).
Cao, Y. et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2, 762–769 (2016).
Oruc, Z. & Kaplan, M. A. Effect of exercise on colorectal cancer prevention and treatment. World J. Gastrointest. Oncol. 11, 348–366 (2019).
Durko, L. & Malecka-Panas, E. Lifestyle modifications and colorectal cancer. Curr. Colorectal Cancer Rep. 10, 45–54 (2014).
Derry, M. M., Raina, K., Agarwal, C. & Agarwal, R. Identifying molecular targets of lifestyle modifications in colon cancer prevention. Front. Oncol. 3, 119 (2013).
Chan, D. S. et al. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS ONE 6, e20456 (2011).
Sugimura, T., Wakabayashi, K., Nakagama, H. & Nagao, M. Heterocyclic amines: mutagens/carcinogens produced during cooking of meat and fish. Cancer Sci. 95, 290–299 (2004).
Aune, D. et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 343, d6617 (2011).
Bingham, S. A. et al. Dietary fibre in food and protection against colorectal cancer in the European prospective investigation into cancer and nutrition (EPIC): an observational study. Lancet 361, 1496–1501 (2003).
Yue, Y. et al. Prospective evaluation of dietary and lifestyle pattern indices with risk of colorectal cancer in a cohort of younger women. Ann. Oncol. 32, 778–786 (2021).
de Beer, J. C. & Liebenberg, L. Does cancer risk increase with HbA1c, independent of diabetes? Br. J. Cancer 110, 2361–2368 (2014).
Cavestro, G. M. et al. Delphi initiative for early-onset colorectal cancer (DIRECt) international management guidelines. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.12.006 (2022).
Tanaka, S. et al. JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig. Endosc. 27, 417–434 (2015).
Pimentel-Nunes, P. et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 47, 829–854 (2015).
Draganov, P. V., Wang, A. Y., Othman, M. O. & Fukami, N. AGA Institute clinical practice update: endoscopic submucosal dissection in the United States. Clin. Gastroenterol. Hepatol. 17, 16–25.e1 (2019).
Kuellmer, A. et al. Endoscopic full-thickness resection for early colorectal cancer. Gastrointest. Endosc. 89, 1180–1189.e1 (2019).
Costas-Chavarri, A. et al. Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. J. Glob. Oncol. 5, 1–19 (2019).
Labianca, R. et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24 (Suppl. 6), vi64–vi72 (2013).
Heald, R. J. The ‘holy plane’ of rectal surgery. J. R. Soc. Med. 81, 503–508 (1988).
Emmanuel, A. & Haji, A. Complete mesocolic excision and extended (D3) lymphadenectomy for colonic cancer: is it worth that extra effort? A review of the literature. Int. J. Colorectal Dis. 31, 797–804 (2016).
Kanemitsu, Y. et al. Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial. J. Clin. Oncol. 39, 1098–1107 (2021).
Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N. Engl. J. Med. 350, 2050–2059 (2004).
Carrato, A. Adjuvant treatment of colorectal cancer. Gastrointest. Cancer Res. 2, S42–S46 (2008).
Lieu, C. et al. Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline. J. Clin. Oncol. 37, 1436–1447 (2019).
Grothey, A. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N. Engl. J. Med. 378, 1177–1188 (2018).
Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016).
Venook, A. P. et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317, 2392–2401 (2017).
Tabernero, J. et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J. Clin. Oncol. 39, 273–284 (2021).
Arnold, D. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 28, 1713–1729 (2017).
Yoshino, T. et al. Rationale for and design of the PARADIGM study: randomized phase III study of mFOLFOX6 plus bevacizumab or panitumumab in chemotherapy-naive patients with RAS (KRAS/NRAS) wild-type, metastatic colorectal cancer. Clin. Colorectal Cancer 16, 158–163 (2017).
Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773–779 (2018).
Peacock, O. et al. Complications after extended radical resections for locally advanced and recurrent pelvic malignancies: a 25-year experience. Ann. Surg. Oncol. 27, 409–414 (2020).
You, Y. N. et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer. Dis. Colon Rectum 63, 1191–1222 (2020).
Giordano, L. et al. Robotic-assisted and laparoscopic sigmoid resection. JSLS https://doi.org/10.4293/JSLS.2020.00028 (2020).
Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731–1740 (2004).
Gerard, J. P. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J. Clin. Oncol. 24, 4620–4625 (2006).
McCarthy, K., Pearson, K., Fulton, R. & Hewitt, J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst. Rev. 12, CD008368 (2012).
Garcia-Aguilar, J. et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 16, 957–966 (2015).
Garcia-Aguilar, J. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J. Clin. Oncol. 40, 2546–2556 (2022).
Yuval, J. B. & Garcia-Aguilar, J. Watch-and-wait management for rectal cancer after clinical complete response to neoadjuvant therapy. Adv. Surg. 55, 89–107 (2021).
Weiser, M. R. et al. A dynamic clinical calculator for estimating conditional recurrence-free survival after total neoadjuvant therapy for rectal cancer and either surgery or watch-and-wait management. JAMA Netw. Open 5, e2233859 (2022).
Stoffel, E. M. et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J. Clin. Oncol. 33, 209–217 (2015).
Herzig, D. et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of inherited polyposis syndromes. Dis. Colon Rectum 60, 881–894 (2017).
Herzig, D. O. et al. Clinical practice guidelines for the surgical treatment of patients with Lynch syndrome. Dis. Colon Rectum 60, 137–143 (2017).
Grothey, A. Pembrolizumab in MSI-H-dMMR advanced colorectal cancer – a new standard of care. N. Engl. J. Med. 383, 2283–2285 (2020).
Diaz, L. A. Jr et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659–670 (2022).
Sinicrope, F. A. et al. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502) [abstract]. J. Clin. Oncol. 37 (Suppl. 15), e15169 (2019).
André, T., Cohen, R. & Salem, M. E. Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability/mismatch repair deficiency in 2022. Am. Soc. Clin. Oncol. Educ. Book 42, 233–241 (2022).
Sargent, D. J. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28, 3219–3226 (2010).
de Rosa, N. et al. DNA mismatch repair deficiency in rectal cancer: benchmarking its impact on prognosis, neoadjuvant response prediction, and clinical cancer genetics. J. Clin. Oncol. 34, 3039–3046 (2016).
Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363–2376 (2022).
Heneghan, H. M., Martin, S. T. & Winter, D. C. Segmental vs extended colectomy in the management of hereditary nonpolyposis colorectal cancer: a systematic review and meta-analysis. Colorectal Dis. 17, 382–389 (2015).
Anele, C. C. et al. Risk of metachronous colorectal cancer following colectomy in Lynch syndrome: a systematic review and meta-analysis. Colorectal Dis. 19, 528–536 (2017).
You, Y. N. et al. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life. Dis. Colon Rectum 51, 1036–1043 (2008).
Etchegary, H., Dicks, E., Watkins, K., Alani, S. & Dawson, L. Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers. Hereditary Cancer Clin. Pract. 13, 10 (2015).
Velikova, G., Stark, D. & Selby, P. Quality of life instruments in oncology. Eur. J. Cancer 35, 1571–1580 (1999).
Ahnen, D. J. et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin. Proc. 89, 216–224 (2014).
Kneuertz, P. J. et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 150, 402–409 (2015).
You, Y. N. et al. Young-onset rectal cancer: presentation, pattern of care and long-term oncologic outcomes compared to a matched older-onset cohort. Ann. Surg. Oncol. 18, 2469–2476 (2011).
Soliman, H. & Agresta, S. V. Current issues in adolescent and young adult cancer survivorship. Cancer Control. 15, 55–62 (2008).
Perl, G. et al. Young patients and gastrointestinal (GI) tract malignancies – are we addressing the unmet needs. BMC Cancer 16, 630 (2016).
Avis, N. E., Crawford, S. & Manuel, J. Quality of life among younger women with breast cancer. J. Clin. Oncol. 23, 3322–3330 (2005).
Werner-Lin, A. et al. Waiting and “weighted down”: the challenge of anticipatory loss for individuals and families with Li-Fraumeni syndrome. Fam. Cancer 19, 259–268 (2020).
Stupart, D., Win, A. K., Winship, I. M. & Jenkins, M. Fertility after young-onset colorectal cancer: a study of subjects with Lynch syndrome. Colorectal Dis. 17, 787–793 (2015).
Burton-Chase, A. M. et al. Health-related quality of life in colorectal cancer survivors: are there differences between sporadic and hereditary patients. J. Patient Rep. Outcomes 2, 21 (2017).
Sun, R. et al. The incidence and risk factors of low anterior resection syndrome (LARS) after sphincter-preserving surgery of rectal cancer: a systematic review and meta-analysis. Support. Care Cancer 29, 7249–7258 (2021).
Al Rashid, F. et al. The impact of bowel dysfunction on health-related quality of life after rectal cancer surgery: a systematic review. Tech. Coloproctol. https://doi.org/10.1007/s10151-022-02594-0 (2022).
Bailey, C. E. et al. Functional deficits and symptoms of long-term survivors of colorectal cancer treated by multimodality therapy differ by age at diagnosis. J. Gastrointest. Surg. 19, 180–188 (2015).
Rashedi, A. S. et al. Survey of third-party parenting options associated with fertility preservation available to patients with cancer around the globe. JCO Glob. Oncol. https://doi.org/10.1200/JGO.2017.009944 (2020).
Corrigan, K. L. et al. Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery. Cancer https://doi.org/10.1002/cncr.34220 (2022).
Morton, S. M. et al. Cohort profile: growing up in New Zealand. Int. J. Epidemiol. 42, 65–75 (2013).
Connelly, R. & Platt, L. Cohort profile: UK Millennium Cohort Study (MCS). Int. J. Epidemiol. 43, 1719–1725 (2014).
Kooijman, M. N. et al. The Generation R Study: design and cohort update 2017. Eur. J. Epidemiol. 31, 1243–1264 (2016).
Cirillo, P. M. & Cohn, B. A. Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. Circulation 132, 1234–1242 (2015).
Fuchs, C. S. et al. A prospective study of family history and the risk of colorectal cancer. N. Engl. J. Med. 331, 1669–1674 (1994).
Clavel-Chapelon, F. et al. E3N, a French cohort study on cancer risk factors. Eur. J. Cancer Prev. 6, 473–478 (1997).
Møller, P. et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 66, 464–472 (2017).
Lynch, H. et al. Milestones of Lynch syndrome: 1895–2015. Nat. Rev. Cancer 15, 181–194 (2015).